Biomarkers

Area of Science:

• Neuroscience
• Gerontology
• Sleep Medicine

Background:

• Alzheimer's Disease (AD) is a major global health challenge.
• Sleep disturbances like insomnia and Sleep-Disordered Breathing (SDB) are potential modifiable risk factors for AD.
• The interplay between sleep issues, AD biomarkers, and cognitive decline needs further investigation.

Purpose of the Study:

• To investigate the relationship between self-reported insomnia and SDB and neuroimaging biomarkers in AD.
• To explore how sleep disturbances affect cognitive decline across the AD continuum.

Main Methods:

• Analysis of data from 1510 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI).
• Examination of tau and amyloid PET scans, structural MRI, and cognitive scores (ADAS-Cog).
• Statistical analysis controlling for demographic and clinical factors to assess the impact of sleep disturbances.

Main Results:

• Sleep disturbances significantly impact tau deposition in AD-vulnerable brain regions.
• Sleep-Disordered Breathing (SDB) shows a more pronounced and earlier effect on AD pathology and cognitive decline than insomnia.
• These effects are particularly evident in middle stages of AD.

Conclusions:

• Sleep disturbances, especially SDB, are linked to increased tau burden and cognitive decline in AD.
• Targeting sleep disturbances, particularly SDB, is crucial for mitigating AD pathology and cognitive impairment.
• Early diagnosis and intervention for sleep disturbances may offer significant therapeutic benefits for AD patients.